- Home
- APRE vs KZIA Comparison
APRE vs KZIA Comparison
Compare APRE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- KZIA
- Stock Information
- Founded
- APRE 2006
- KZIA 1994
- Country
- APRE United States
- KZIA Australia
- Employees
- APRE N/A
- KZIA N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- KZIA Health Care
- Exchange
- APRE Nasdaq
- KZIA Nasdaq
- Market Cap
- APRE 8.3M
- KZIA 9.0M
- IPO Year
- APRE 2019
- KZIA 1999
- Fundamental
- Price
- APRE $1.51
- KZIA N/A
- Analyst Decision
- APRE Strong Buy
- KZIA Strong Buy
- Analyst Count
- APRE 1
- KZIA 3
- Target Price
- APRE $20.00
- KZIA $16.00
- AVG Volume (30 Days)
- APRE 50.3K
- KZIA 185.0K
- Earning Date
- APRE 11-06-2025
- KZIA 11-14-2025
- Dividend Yield
- APRE N/A
- KZIA N/A
- EPS Growth
- APRE N/A
- KZIA N/A
- EPS
- APRE N/A
- KZIA N/A
- Revenue
- APRE $841,012.00
- KZIA $1,549,158.00
- Revenue This Year
- APRE N/A
- KZIA N/A
- Revenue Next Year
- APRE N/A
- KZIA $49.25
- P/E Ratio
- APRE N/A
- KZIA N/A
- Revenue Growth
- APRE N/A
- KZIA 248983.08
- 52 Week Low
- APRE $1.37
- KZIA $2.86
- 52 Week High
- APRE $5.01
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- APRE 51.04
- KZIA 41.85
- Support Level
- APRE $1.40
- KZIA $6.79
- Resistance Level
- APRE $1.53
- KZIA $7.45
- Average True Range (ATR)
- APRE 0.08
- KZIA 0.50
- MACD
- APRE 0.01
- KZIA 0.00
- Stochastic Oscillator
- APRE 67.77
- KZIA 38.95
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.